dNovo

dNovo aimed to revolutionize hair loss treatment through the creation of new hair follicles using cellular reprogramming. Leveraging technology developed at Stanford and Harvard, dNovo sought to convert patient-derived cells, such as those from blood, skin, or fat, into medically relevant cell types. Their primary focus was to generate new hair follicles, a departure from existing hair loss solutions that primarily focus on maintaining existing hair. This innovative approach involved a patent-pending process to produce hair 'de novo.' While their initial objective centered on hair loss, dNovo envisioned expanding their cellular reprogramming technique to create various cells, tissues, and organs on demand, potentially addressing age-related tissue loss and organ failure. However, the company is now inactive.